ㆍDAILY PROGRAMㆍPROGRAM AT A GLANCE

DAILY PROGRAM

08:30-09:50

Pre-Congress Symposium

  • 08:30-08:45

  • Updates on Epidemiology and the Natural Course of Viral Hepatitis in the Asian-Pacific Region (HBV)

  • 08:45-09:00

  • Updates on Epidemiology and Natural Course of Viral Hepatitis in the Asian-Pacific Region (HCV)

  • 09:00-09:15

  • Clinical Impacts of Epidemiological Growth of Nonalcoholic Fatty Liver Disease in the Asian-Pacific Region

  • 09:15-09:30

  • Cure of Viral Hepatitis: Definition and Sub-Classification

  • 09:30-09:40

  • Overview of Barriers to Hepatitis B Virus Cure

  • 09:40-09:50

  • Overview of Barriers to Hepatitis C Virus Cure

  • 10:00-10:20

  • Opening Ceremony

10:20-10:50

Presidential Lecture

  • 10:20-10:50

  • How to Encourage and Organize Young Members of a Liver Society

10:50-11:50

Symposium 1-1. Hepatitis Elimination by 2030: Where Are We Now?

  • 10:50-11:05

  • Hepatitis B Virus 2023: New Therapeutic Strategies against an Old Foe

  • 11:05-11:20

  • Hepatitis C Virus 2023: The Road to Elimination of the Hepatitis C Virus

  • 11:20-11:35

  • Optimizing Hepatitis B and C Treatment in Resource-Limited Settings

  • 11:35-11:50

  • Global Care Cascade for Chronic Hepatitis B and C Virus Infection

  • 11:50-12:50

  • Luncheon Symposium

12:50-13:20

State-of-the-Art Lecture I

  • 12:50-13:20

  • A 30-Year Journey of Hepatitis C Virus Research: from Discovery to a Cure

13:20-14:20

Keynote Lecture 1. Viral Hepatitis Elimination: Where Do We Stand? It Has Already Reached Halfway by 2030

  • 13:20-13:40

  • Notable Milestones Achieved Towards Viral Hepatitis Elimination to Date

  • 13:40-14:00

  • Efforts and Strategy to Accelerate Progress Towards Viral Hepatitis Elimination by 2030

  • 14:00-14:20

  • It Is Time for a Simplified Approach to Hepatitis B Elimination

  • 14:20-14:40

  • Coffee Break

14:40-16:00

PG Course 1. On the Way to HBV Elimination, What Is a Recent Issue?

  • 14:40-15:00

  • Strategies to Cure Chronic Hepatitis B: Stopping Oral Antivirals or Interferon Add-on/Switch Therapies

  • 15:00-15:20

  • Application of Current Biomarkers to Guide Anti-HBV Treatment

  • 15:20-15:40

  • The Optimal Treatment Consideration of Hepatitis B Virus Gray Zone Patients

  • 15:40-16:00

  • Risk Factors and Biomarkers for HCC Development after a Cure of Chronic Hepatitis B

  • 16:00-16:20

  • Coffee Break

16:20-17:40

PG Course 2. Treatment of Viral Hepatitis, What Progress Is Being Made?

  • 16:20-16:40

  • Current Optimal Treatment for Chronic Hepatitis C Virus Infection in Various Clinical Situations

  • 16:40-17:00

  • Strategies for the Elimination of Hepatitis C Virus Infection

  • 17:00-17:20

  • Current and Emerging Therapeutic Approaches to Hepatitis D Virus Infection

  • 17:20-17:40

  • Hepatitis E: Who Should Be Treated?

10:50-11:50

EAST ASIA Joint Symposium: Hepatitis C Virus Elimination

  • 10:50-11:05

  • Cost-Effectiveness Hepatitis C Virus Screening and Treatment in South Korea

  • 11:05-11:20

  • Clinical Challenges in Hepatitis C Virus Management in Japan

  • 11:20-11:35

  • How Would China Achieve WHO's Target of Eliminating the Hepatitis C Virus?

  • 11:35-11:50

  • Linkage-to-Care and Follow-Up Strategy for Hepatitis C Virus Infection in Taiwan

  • 11:50-12:50

  • Luncheon Symposium 2

  • 13:20-14:20

  • Special Symposium

  • 14:20-14:40

  • Coffee Break

14:40-16:00

Symposium 1-2. Immunology and Immunotherapy of Viral Hepatitis

  • 14:40-15:00

  • Immunological Characteristics of Hepatitis B Virus Infection

  • 15:00-15:20

  • Novel Immunological Therapeutics for the Cure of Hepatitis B Virus Infection

  • 15:20-15:40

  • Immunological Scars after Hepatitis C Virus Clearance

  • 15:40-16:00

  • T-Cell Responses against Hepatitis Viruses

  • 16:00-16:20

  • Coffee Break

16:20-17:40

Symposium 1-3. Emerging Antivirals for Hepatitis B Virus Cure

  • 16:20-16:40

  • Updates on Drugs for Hepatitis B Virus Entry and/or Post-Entry Inhibition

  • 16:40-17:00

  • Updates on Hepatitis B Virus Capsid Assembly Inhibitors

  • 17:00-17:20

  • Updates on Drugs Targeting Hepatitis B Virus RNAs: ASOs and siRNA

  • 17:20-17:40

  • Updates on cccDNA Disruptors

10:50-11:50

SIG 1.

13:20-14:20

SIG 2. cccDNA and Hepatitis B Virus Integration: Stumbling Blocks for Hepatitis B Virus Cure

  • 13:20-13:40

  • Hepatitis B Virus cccDNA: Mechanism of Its Formation and Therapeutic Targets

  • 13:40-14:00

  • Hepatitis B Virus Integration and Liver Cancer

  • 14:00-14:20

  • Genome Editing for cccDNA and Integrated Hepatitis B Virus

  • 14:20-14:40

  • Coffee Break

14:40-16:00

Oral Presentation